Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 viruslike particle vaccine An open-label phase i clinical trial

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 469-475

  Hu, Yue Mei ^a   Huang, Shou Jie ^b   Chu, Kai ^a   Wu, Ting ^b   Wang, Zhong Ze ^c   Yang, Chang Lin ^c   Cai, Jia Ping ^c   Jiang, Han Min ^c   Wang, Yi Jun ^c   Guo, Meng ^d   Liu, Xiao Hui ^d   Huang, Hong Jiang ^d,e   Zhu, Feng Cai ^a   Zhang, Jun ^b   Xia, Ning Shao ^b  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b XIAMEN UNIVERSITY   (China)

^c Dongtai Center for Disease Control and Prevention   (China)

^d Xiamen Innovax Biotech   (China)

^e Xiamen Siming District Center for Disease Control and Prevention   (China)

Author keywords

Clinical trial; Human papillomavirus; Phase I; Safety; Vaccine

Indexed keywords

CECOLIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; CAPSID PROTEIN; DRUG CARRIER; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN; VIRUS LIKE PARTICLE VACCINE;

ADULT; ANAPHYLAXIS; ARTICLE; BODY TEMPERATURE DISORDER; CHINA; COUGHING; DIARRHEA; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; ESCHERICHIA COLI; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INJECTION SITE PAIN; MIDDLE AGED; MYALGIA; NAUSEA; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PRURITUS; RISK ASSESSMENT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS PARTICLE; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE VECTOR; GENETICS; IMMUNOLOGY; PATHOLOGY;

ADOLESCENT; ADULT; CAPSID PROTEINS; CHINA; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84896959994     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26846     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi. org/10.3322/caac.20107
2. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380:1840-50; PMID:23079588; http:// dx.doi.org/10.1016/S0140-6736(12)60919-2
3. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R; Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513-7; PMID:18364507; http://dx.doi.org/10.1093/jnci/djn044
4. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-6; PMID:11410191; http://dx.doi. org/10.1016/S0140-6736(00)04956-4 (Pubitemid 32539115)
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI )1096 -9896 (199909)189 : 1<12 : :AIDPATH431>3.0.CO;2-F (Pubitemid 29406813)
6. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009; 20:1705-13; PMID:19705288; http://dx.doi.org/10.1007/s10552-009-9422-z
7. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27; PMID:12571259; http:// dx.doi.org/10.1056/ NEJMoa021641 (Pubitemid 36159887)
8. Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 2002; 100:327-31; PMID:12115548; http://dx.doi. org/10.1002/ijc.10506 (Pubitemid 34728991)
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/ NEJMoa061741
10. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/ NEJMoa061760
11. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi. org/10.1016/S0140-6736(07)60946-5 (Pubitemid 46977438)
12. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi. org/10.1016/S0140- 6736(09)61248-4
13. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(Suppl 5):F123-38; PMID:23199956; http://dx.doi.org/10.1016/j. vaccine.2012.04.108
14. Wei M-X, Li SW, Huang B, Shen WT, Su YZ, Zhang CH, Gu Y, Du HL, Zhang J, Xia NS. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity] [in Chinese]. Bing Du Xue Bao 2009; 25:245-50; PMID:19769155
15. Xie M-H, Li S-W, Shen W-T, Li Z-Y, Zhuang Y-D, Mo X-B, Gu Y, Wu T, Zhang J, Xia N. [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli] [in Chinese]. Sheng Wu Gong Cheng Xue Bao 2009; 25:1082-7; PMID:19835152
16. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895-902; PMID:20728932; http://dx.doi. org/10.1016/S0140-6736(10)61030-6
17. CFDA. Adverse reaction grading standards guideline for prophylactic vaccine clinical trial. 2005 Available from: http://www.sda.gov.cn/WS01/CL1616/ 83435. html.
18. Corp. MSD. GARDASIL Prescribing Information.2013 Available from: http://www. merck.com/product/usa/picirculars /g/gardasil/gardasilpi.pdf
19. GlaxoSmithKline. CERVARIX Prescribing Information. 2012 Available from: http://us.gsk. com/products/assets/uscervarix.pdf
20. Miller NB. Clinical Review of Biologics License Application for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine (S. cerevisiae) (STN 125126 GARDASIL), manufactured by Merck, Inc. 2006 Available from: http://www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM111287.pdf
21. Nancy B. Miller, Roberts J. Clinical Review of Biologics License Application for Human Papillomavirus 16, 18 L1 Virus Like Particle Vaccine, AS04 Adjuvant-Adsorbed (Cervarix). 2009[http:// www.fda.gov/downloads/ biologicsbloodvaccines/ vaccines/approvedproducts/ucm237976.pdf ].
22. Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013; In press; PMID:24125746; http:// dx.doi.org/10.1016/j. tibtech.2013.09.002.
23. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991; 60:1445-56; PMID:1663794; http:// dx.doi.org/10.1016/S0006-3495(91)82181-6
24. Zhao Q, Modis Y, High K, Towne V, Meng Y, Wang Y, Alexandroff J, Brown M, Carragher B, Potter CS, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J 2012; 9:52; PMID:22356831; http://dx.doi.org/10.1186/1743- 422X-9-52
25. Salunke DM, Caspar DL, Garcea RL. Self-assembly of purified polyomavirus capsid protein VP1. Cell 1986; 46:895-904; PMID:3019556; http://dx.doi. org/10.1016/0092-8674(86)90071-1 (Pubitemid 16027938)
26. Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009; 8:17; PMID:19317892; http://dx.doi. org/10.1186/1475-2859-8-17
27. Zhang J, Shih JW, Wu T, Li SW, Xia NS. Development of the hepatitis E vaccine: from bench to field. Semin Liver Dis 2013; 33:79-88; PMID:23564392; http:// dx.doi.org/10.1055/s-0033-1338116
28. Park SB. Hepatitis E vaccine debuts. Nature 2012; 491:21-2; PMID:23128204; http://dx.doi. org/10.1038/491021a